A breast cancer patient with bone metastases showed a marked response to treatment with a bisphosphonate, an inhibitor of osteoclastic bone resorption. The patient was admitted to our hospital with hypercalcemia, widespread bone metastases and severe disseminated intravascular coagulation (DIC). Wetreated her conservatively with pamidronate and gabexate mesilate, because the patient had refused any anti-cancer chemotherapy. She showed marked improvement in performance status, hypercalcemia, DIC and tumor markers, whereas splenomegaly due to metastasis progressed. These results suggest that pamidronate has the potential to suppress metastatic tumor growth selectively in bone. (Internal Medicine 36: 926-930, 1997) 
Introduction
Breast cancer is knownto frequently metastasize to bone. Recent studies suggest that a bisphosphonate, a potent inhibitor of osteoclastic bone resorption, can suppress and prevent bone lesions of humanbreast cancer in an experimental model (1) . Clinical data showthat bisphosphonates prevent and inhibit the progression of bone diseases associated with various malignancies (2, 3) , but it has not been proven as to whether bisphosphonates exert their effects on the growth of cancer cells selectively in a bone environment or not. Here we report a case of breast carcinoma with widespread bone metastases. Chemotherapy was refused by the patient which allowed us to evaluate the selective effect of a bisphosphonate on the clinical outcome.
Case Report A55-year-old Japanese womanwas admitted to our hospital with systemic bone pain and elevated serum carcinoembryonic antigen (CEA) [ Table 1 and Fig. 1 , respectively. A bone marrow biopsy revealed a diffuse invasion of adenocarcinoma, and a 99m-Tcbone scan suggested the presence of widely disseminated metastases (Fig. 2) . No primary site of malignancy was detected based on the results of chest, abdominal and pelvic computed tomography (CT), abdominal and breast ultrasonography and esophagogastric endoscopy. Because the patient and her family refused any anti-cancer therapy, we attempted only to control DICand hypercalcemia. After administration of 30 mg of pamidronate on the 7th hospital day, both PS and DIC score (according to the Health and Welfare Ministry of Japan criteria) improved dramatically (Fig. 3) . Serum levels of CEAand carbohydrate antigen (CA) 125 decreased along with normalization of cCa, whereas we observed a gradual progression ofsplenomegaly on ultrasonography. In addition to pamidronate, gabexate mesilate was given for DIC from the time of admission until 10 days before being discharged. After 2 months of hospitalization, she was discharged with a PS of grade 1, when she also had mild spleno-Pamidronate Suppresses Bone Metastasis erythrocyte sedimentation rate, FDP: fibrin degradation product.
megaly (3 cm below the left costal margin) (Figs. 1, 3). As an outpatient she was generally well and completely free of bone pain. Attempts at obtaining a bone marrow biopsy were refused by the patient. She was re-admitted 2 months later with a recurrence of hypercalcemia, at which time the spleen was enlarged to the level of the umbilicus. Whenpamidronate (30 mg) was given again cCa decreased from 14.4 to 10.0 mg/dl and DIC scores improved from 4 to 3, however PS and tumor markers did not improve and splenomegaly worsened (Fig. 3 ). Hypercalcemia and DIC accelerated and her general condition rapidly deteriorated. She died 5 months after the first admission. An autopsy revealed that the primary site of the cancer was the breast (invasive lobular carcinoma) and that prominent metastatic lesions were observed in the bone and the spleen.
Discussion
Wepresented a case of breast cancer with widespread bone metastases in which treatment with a bisphosphonate caused a dramatic improvement of clinical manifestations , paraneoplastic syndromesand tumor markers, while extra-skeletal lesions did not improve. The efficacy of pamidronate in the reduction of bone pain and improvement of PS and the quality of life in patients with stage III multiple myeloma (2) and subsequently in patients with breast cancer has recently been reported (4) . There is also a preliminary report suggesting that in patients with breast cancer, treatment with pamidronate lessened complaints concerning bone pain and resulted in improvements in bone resorption markers without the administration of antineoplastic agents (3). The possibility of natural regression in the patient with a PS of grade 4 is thought to be rare and no recent reports of such an occurrence exist. It cannot be ruled out however, that some humoral factors, such as TGF-(5 and angiostatin produced by the primary tumor itself, alter the microenvironment in bone (5 In view of the previous studies on bisphosphonates in bone metastasis, this case has two important features. The first feature is that prominent metastatic lesions were observed in the bone at autopsy and also in the spleen, which was discolored and markedly swollen with a diffuse invasion of cancer cells. In the present patient, splenomegaly was not seen on admission; it might have gradually worsened even though her general condition improved. The second feature is that the bisphosphonate exerted remarkable effects on skeletal complications, whereas it had no beneficial effect on the extra-skeletal metastases. In this case the therapeutic effects ofpamidronate on bone marrowwerejudged by clinical manifestations, such as immediate improvement of DIC and severe anemia which were thought to be caused by dysfunction of bone marrow due to diffuse invasion of cancer cells. Biochemical markers of bone resorption and formation were not measured. Sasaki et al recently reported that in a bone metastasis model of humanbreast cancer in nude mice, a bisphosphonate not only prevented but also suppressed the growth of cancer cells in bone without affecting extra-skeletal lesions (1) . The mechanism by which bisphosphonates suppress cancer cell growth in the bone environment remains elusive. Interactions between bone and cancer cells play an important role in the progression of bone metastases through the recruitment and activation of osteoclasts as well as the supply of growth factors for cancer cells (6, 7 resorption markers persisted for a few years (1 1 , 12) . In another study, it was shown that there was no difference in the effect between single and multiple intravenous infusions of bisphosphonates in the treatment of hypercalcemia of malignancy (13) . The sustained effect may be related to the fact that intravenously injected pamidronate was adsorbed on the bone surface for a long time, possibly years. However, one must rememberthat the effects of bisphosphonates vary among individuals, and that this case may belong to a highly sensitive group.
The next point is that a marked decrease in tumor markers was observed despite the fact that extra-skeletal lesions grew gradually. Three months after the administration ofpamidronate, tumor markers as well as other laboratory parameters began to increase again. Some studies reported that CA15-3 and/or CEA, parameters of disease activity, decreased after administration ofabisphosphonate (14, 15). Itcan be speculatedthatthe rate of tumor reduction in bone was so muchfaster and greater than the rate of tumor growth in extra-skeletal lesions that tumor markers, which reflect total tumor mass in the body, decreased rapidly. Whenthe latter overtakes the former, it is hypothesized that tumor markers maybegin to increase again. In the case of patients whosetumor volume in bone is smaller than that of the extra-skeletal lesion, a decrease in tumor markers maynot be observed. However, it can be said that the efficacy of bisphosphonates has not yet been proved. Hortobagyi et al (4) and van Holten-Verzantvoort et al (16) have concluded that
bisphosphonates have no anti-cancer effect. We administered 1 ,000-2,000 mg/day of gabexate mesilate during the patient' s hospital admission. Since gabexate mesilate has been reported to suppress the growth of cancer cells in vitro (17, 1 8) , there exists the possibility that gabexate enhanced the effect of the bisphosphonate in the present case. Our experience with this case suggests that bisphosphonate has the potential as an anti-cancer agent by inhibiting tumor cell growth in the skeletal microenvironment. Further study is necessary to determine whether bisphosphonates stimulate the growth of cancer cells in non-skeletal tissues, and therefore whether the overall effect of bisphosphonates is beneficial to cancer patients.
